Mirum Pharmaceuticals, Inc. (MIRM) - Q1 2025 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for the period ended March 31, 2025. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, commercializing three approved medicines: LIVMARLI (maralixibat), Cholbam (cholic acid), and Ctexli (chenodiol, approved by the FDA in February 2025 for adults with CTX). The company also has a pipeline including volixibat and MRM-3379.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $111,585 | $69,222 |
| Net Loss | $(14,677) | $(25,279) |
| Net Loss Per Share | $(0.30) | $(0.54) |
| Operating Cash Flow | $(1,961) | $15,212 |
| Cash & Investments (Unrestricted) | $298,600 | $292,800 |
| Convertible Notes (Principal) | $316,244 | $316,250 |
Note: Revenue consists entirely of product sales. Gross margin was approximately 79% ($88.6M revenue less $23.0M cost of sales).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 61% ($42.4M) year-over-year. Livmarli sales grew 69% to $73.2M, and Bile Acid Medicines sales grew 47% to $38.4M.
- Improved Profitability: Net loss narrowed by 42% to $14.7M, driven by revenue growth outpacing expense increases.
- Expense Increases:
- R&D: Increased $13.8M (43%) to $46.0M, primarily due to a $5.0M milestone payment for the Livmarli EXPAND study and increased volixibat trial costs.
- SG&A: Increased $12.1M (26%) to $57.7M, driven by higher personnel costs and marketing spend for Bile Acid Medicines.
- Cost of Sales: Increased $5.2M (29%) to $23.0M due to higher royalties and API commitment losses, partially offset by lower unit costs on acquired inventory.
- Cash Flow: Operating cash flow turned negative ($2.0M used) compared to a $15.2M inflow in Q1 2024, largely due to a $16.8M increase in accounts receivable and timing of payments.
Outlook, Risks, and Unusual Items
- Convertible Notes: The 4.00% Convertible Senior Notes due 2029 are currently convertible at the option of holders for the quarter ending June 30, 2025, as the stock price exceeded 130% of the conversion price. The company may settle conversions in cash, stock, or a combination.
- Liquidity: Management believes unrestricted cash and investments of $298.6M are sufficient to fund operations for at least 12 months.
- Regulatory Milestones: FDA approval for Ctexli (chenodiol) was received in February 2025. Livmarli received approval in Japan in March 2025.
- Risks: Key risks include reliance on third-party manufacturers, potential dilution from note conversions, competition from generic/compounded products for Bile Acid Medicines, and the uncertainty of clinical trial outcomes for volixibat and MRM-3379.
Investor Verification Checklist
- Convertible Note Conversion: Verify if holders have elected to convert notes in Q2 2025 and the settlement method (cash vs. stock) to assess dilution or cash impact.
- Accounts Receivable: Monitor the $95.9M accounts receivable balance (up $17.6M from Q4 2024) to ensure collection trends align with revenue recognition.
- Ctexli Commercialization: Track initial sales performance of Ctexli following its February 2025 FDA approval.
- Volixibat Trial Progress: Confirm enrollment status for the VISTAS (PSC) and VANTAGE (PBC) Phase 2b trials.
- Inventory Commitments: Review future firm purchase commitments for APIs, as excess commitments contributed to cost of sales increases.